Braintree, MA, United States of America

Lei Wang

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2019-2023

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Lei Wang: Innovator in Antibody Development

Introduction

Lei Wang is a prominent inventor based in Braintree, MA (US), known for his significant contributions to the field of biotechnology. With a focus on developing innovative therapeutic solutions, he has been instrumental in advancing the understanding and application of antibodies in medical treatments. Lei holds a total of 3 patents, showcasing his dedication to innovation and research.

Latest Patents

Among his latest patents, Lei Wang has developed Anti-PD-1 antibodies. These antibodies bind to programmed cell death protein 1 (PD-1), which plays a crucial role in regulating immune responses. The patents disclose compositions comprising such antibodies, as well as methods of making and using them. This groundbreaking work has the potential to impact cancer treatment significantly.

Career Highlights

Lei Wang is currently associated with Pd-1 Acquisition Group, LLC, where he continues to push the boundaries of antibody research. His work is characterized by a commitment to improving therapeutic options for patients, particularly in the realm of immunotherapy.

Collaborations

Lei collaborates with Najmia Amirina, a talented woman in the field, contributing to the innovative projects at their company. Their combined expertise enhances the research and development efforts within the organization.

Conclusion

In summary, Lei Wang is a dedicated inventor whose work in developing Anti-PD-1 antibodies represents a significant advancement in biotechnology. His contributions are paving the way for new therapeutic approaches in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…